SCHEMBL12409196

SCHEMBL12409196

CC(C)(C)c1cc(Cl)ccc1OCCCCNC(=O)c1ccc(O)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.53
ALDH1A1 P00352 5/20 0.53
LMNA P02545 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
MAPK1 P28482 3/20 0.51
HTT P42858 1/20 0.51
ESRRG P62508 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
GAA P10253 2/20 0.47
RAB9A P51151 1/20 0.43
GSK3B P49841 1/20 0.42
CNR2 P34972 1/20 0.41
RHOC P08134 1/20 0.41
RHOA P61586 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409199 0.89 KDM4E (0.53) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL12409197 0.85 ESRRG (0.47) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL2173939 0.84 KDM4E (0.61) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL12409202 0.82 KDM4E (0.55) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL2175172 0.80 RAB9A (0.48) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL12409191 0.76 KDM4E (0.62) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL12409201 0.74 KDM4E (0.43) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL10184817 0.74 CYP1A2 (0.59) ALDH1A1SMN1; SMN2KMT2AMEN1HTT
SCHEMBL13894563 0.73 KDM4E (0.78) KDM4EALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL29178485 0.72 L3MBTL1 (0.60) ALDH1A1SMN1; SMN2KMT2AMEN1ESRRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973079-B2 Methods and compounds for treating retinol-related diseases REVISION THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-7973079-B2 Methods and compounds for treating retinol-related diseases REVISION THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-20090088435-A1 METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2009-04-02 US disclosed
US-20090088435-A1 METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088435-A1 METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES RBP1, RBP4, ALDH1A2 KDM4E 4096/4885ALDH1A1 40/4885LMNA 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.